Skip to main content
. 2016 Jul 16;2:133–140. doi: 10.1016/j.pvr.2016.07.002

Fig. 3.

Fig. 3

A. Overall survival (OS) and B. Progression free survival (PFS) of OPSCC patients by HPV-driven and HPV non-driven status (assessed in 61/63 cases). The continuous line refers to patients with HPV-driven OPSCC, the dotted line refers to patients with HPV-non driven OPSCC. The patients with HPV-driven tumors showed a trend (P=0.09) for better OS (A) and a significant (P=0.016) difference for PFS (B).